Rafael Zini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rafael Zini has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
André Furtado de Ayalla Rodrigues
Faculdade Pernambucana de Saúde: Faculdade Pernambucana de Saude
1 shared publication- André Furtado de Ayalla Rodrigues
Faculdade Pernambucana de Saúde, Recife, Brazil
1 shared publication Gustavo Bonini Castellana
University of Sao Paulo: Universidade de Sao Paulo
1 shared publication- Gustavo Bonini Castellana
University of Sao Paulo, Sao Paulo, Brazil
1 shared publication - João Mauricio Castaldelli-Maia
Departamento de Psiquiatria, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil
1 shared publication João Maurício Castaldelli-Maia
University of Sao Paulo: Universidade de Sao Paulo
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by Springer Nature in Sports Medicine - Open
- Vol. 12 (1)
Prescribing Antidepressants for Elite Athletes: Is There Evidence to Support Best Practices in Sports Psychiatry? A Scoping Review
Elite athletes face unique mental health challenges, yet the use of antidepressants in this population remains underresearched. Despite the prevalence of depressive and anxiety symptoms, there are no specific pharmacological guidelines tailored to athletes’ mental health needs or performance demands. This scoping review aimed to explore the current literature on the use of antidepressant medications among elite athletes with symptoms of or who were diagnosed with depressive or anxiety disorders, focusing on treatment effectiveness, safety, performance, and, mainly, the athlete’s well-being. A systematic search of PubMed, Embase, and PsycINFO (February 18–20, 2025) was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews (PRISMA-ScR) guidelines. Predefined terms related to athletes, antidepressants, and psychiatric disorders were employed. Studies were included if they involved elite athletes treated with antidepressants for major depressive disorder, bipolar depression, or generalized anxiety disorder. The data were charted and narratively synthesized. Among the 34,131 records screened, 15 met the inclusion criteria: 11 narrative reviews, 2 systematic reviews, 1 survey, and 1 position statement. Most studies provide recommendations on the basis of the general population, offering limited data on elite athletes with formal diagnoses. Few studies have reported treatment durations or mental health outcomes. While performance effects have been emphasized, psychological recovery is rarely addressed. Selective serotonin reuptake inhibitors—particularly escitalopram, fluoxetine, and sertraline—were the most commonly suggested drugs. There is a lack of robust evidence to guide antidepressant use among elite athletes. Future research should prioritize trials involving clinically diagnosed athletes, structured protocols, and outcomes centered on mental health and well-being rather than merely performance.
- 30 June 2026
- Published by Springer Nature in Sports Medicine - Open
- Vol. 12 (1)
Open AccessPrescribing Antidepressants for Elite Athletes: Is There Evidence to Support Best Practices in Sports Psychiatry? A Scoping Review
Elite athletes face unique mental health challenges, yet the use of antidepressants in this population remains underresearched. Despite the prevalence of depressive and anxiety symptoms, there are no specific pharmacological guidelines tailored to athletes’ mental health needs or performance demands. This scoping review aimed to explore the current literature on the use of antidepressant medications among elite athletes with symptoms of or who were diagnosed with depressive or anxiety disorders, focusing on treatment effectiveness, safety, performance, and, mainly, the athlete’s well-being. A systematic search of PubMed, Embase, and PsycINFO (February 18–20, 2025) was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews (PRISMA-ScR) guidelines. Predefined terms related to athletes, antidepressants, and psychiatric disorders were employed. Studies were included if they involved elite athletes treated with antidepressants for major depressive disorder, bipolar depression, or generalized anxiety disorder. The data were charted and narratively synthesized. Among the 34,131 records screened, 15 met the inclusion criteria: 11 narrative reviews, 2 systematic reviews, 1 survey, and 1 position statement. Most studies provide recommendations on the basis of the general population, offering limited data on elite athletes with formal diagnoses. Few studies have reported treatment durations or mental health outcomes. While performance effects have been emphasized, psychological recovery is rarely addressed. Selective serotonin reuptake inhibitors—particularly escitalopram, fluoxetine, and sertraline—were the most commonly suggested drugs. There is a lack of robust evidence to guide antidepressant use among elite athletes. Future research should prioritize trials involving clinically diagnosed athletes, structured protocols, and outcomes centered on mental health and well-being rather than merely performance.
- Open Access
- 12 September 2025
- Published by Springer Nature in Research Square
Prescribing antidepressants for elite athletes: Is there evidence to support best practices in Sports Psychiatry? - A Scoping Review
Background Elite athletes face unique mental health challenges, yet the use of antidepressants in this population remains under-researched. Despite the prevalence of depressive and anxiety symptoms, there are no specific pharmacological guidelines tailored to athletes’ mental health needs or performance demands. Objective This scoping review aimed to explore the current literature on the use of antidepressant medications in elite athletes with symptoms of or diagnosed with depressive or anxiety disorders, focusing on treatment effectiveness, safety, performance, and, mainly, the athlete`s well-being. Methods A systematic search was conducted in PubMed, Embase, and PsycINFO (February 18–20, 2025) following PRISMA-ScR guidelines employing predefined terms related to athletes, antidepressants, and psychiatric disorders. Studies were included if they involved elite athletes treated with antidepressants for Major Depressive Disorder, Bipolar Depression, or Generalized Anxiety Disorder. Data were charted and narratively synthesized. Results Of 34,131 records screened, 15 studies met inclusion criteria: 10 narrative reviews, 3 systematic reviews, 1 survey, and 1 position statement. Most studies extrapolated recommendations from general populations, offering limited data on elite athletes with formal diagnoses. Few reported treatment durations or mental health outcomes. Performance effects were often emphasized, while psychological recovery was rarely addressed. Selective serotonin reuptake inhibitors—particularly escitalopram, fluoxetine, and sertraline—were the most commonly suggested. Conclusion There is a lack of robust evidence to guide antidepressant use in elite athletes. Future research should prioritize trials involving clinically diagnosed athletes, structured protocols, and outcomes centered on mental health and well-being rather than merely performance.
- 12 September 2025
- Published by Springer Nature in Research Square
Open AccessPrescribing antidepressants for elite athletes: Is there evidence to support best practices in Sports Psychiatry? - A Scoping Review
Background Elite athletes face unique mental health challenges, yet the use of antidepressants in this population remains under-researched. Despite the prevalence of depressive and anxiety symptoms, there are no specific pharmacological guidelines tailored to athletes’ mental health needs or performance demands. Objective This scoping review aimed to explore the current literature on the use of antidepressant medications in elite athletes with symptoms of or diagnosed with depressive or anxiety disorders, focusing on treatment effectiveness, safety, performance, and, mainly, the athlete`s well-being. Methods A systematic search was conducted in PubMed, Embase, and PsycINFO (February 18–20, 2025) following PRISMA-ScR guidelines employing predefined terms related to athletes, antidepressants, and psychiatric disorders. Studies were included if they involved elite athletes treated with antidepressants for Major Depressive Disorder, Bipolar Depression, or Generalized Anxiety Disorder. Data were charted and narratively synthesized. Results Of 34,131 records screened, 15 studies met inclusion criteria: 10 narrative reviews, 3 systematic reviews, 1 survey, and 1 position statement. Most studies extrapolated recommendations from general populations, offering limited data on elite athletes with formal diagnoses. Few reported treatment durations or mental health outcomes. Performance effects were often emphasized, while psychological recovery was rarely addressed. Selective serotonin reuptake inhibitors—particularly escitalopram, fluoxetine, and sertraline—were the most commonly suggested. Conclusion There is a lack of robust evidence to guide antidepressant use in elite athletes. Future research should prioritize trials involving clinically diagnosed athletes, structured protocols, and outcomes centered on mental health and well-being rather than merely performance.